文献速递消化道肿瘤与早癌

霍奇金淋巴瘤治疗后结直肠癌中错配修复基因双体细胞突变频繁

Double somatic mutations in mismatch repair genes are frequent in colorectal cancer after Hodgkin's lymphoma treatment.
PubMed 文献 · Gut · 2016-11-08

该研究分析霍奇金淋巴瘤幸存者队列中54例治疗相关结直肠癌(t-CRC)的错配修复蛋白、微卫星不稳定及KRAS/BRAF突变,并与1111例一般人群结直肠癌比较。t-CRC的微卫星不稳定频率更高(24% vs 11%,p=0.003),MSH2/MSH6染色缺失更常见(13% vs 1%,p<0.001);无MLH1启动子甲基化的微卫星不稳定t-CRC中双体细胞错配修复基因突变占7/10(70%),高于一般人群的8/36(22%,p=0.008)。

要点

  • t-CRC的微卫星不稳定频率为24%,高于一般人群的11%(p=0.003)。
  • t-CRC的MSH2/MSH6染色缺失率为13%,高于一般人群的1%(p<0.001)。
  • 无MLH1启动子甲基化的微卫星不稳定t-CRC中双体细胞错配修复基因突变占70%(7/10),一般人群为22%(8/36,p=0.008)。

核心结论

  • t-CRC中微卫星不稳定频率更高,由体细胞错配修复基因突变所致,提示体细胞错配修复基因突变与既往抗癌治疗存在新关联。
  • 微卫星不稳定的t-CRC病例不能归因于林奇综合征。

研究设计与样本

  • 分析霍奇金淋巴瘤幸存者队列中诊断的54例t-CRC,采用免疫组化检测错配修复蛋白、检测微卫星不稳定及KRAS/BRAF突变,并与一般人群结直肠癌队列(n=1111)比较频率。
  • 对微卫星不稳定的t-CRC评估启动子甲基化和错配修复基因突变,通过计算机预测和功能分析评估错配修复基因突变的致病性。

主要发现

  • KRAS和BRAF突变分别存在于41%和15%的t-CRC中。
  • t-CRC的微卫星不稳定频率为24%,一般人群结直肠癌为11%(p=0.003)。
  • t-CRC的MSH2/MSH6染色缺失率为13%,一般人群结直肠癌为1%(p<0.001)。
  • MLH1/PMS2染色缺失和MLH1启动子甲基化在t-CRC与一般人群中同等常见。
  • 无MLH1启动子甲基化的微卫星不稳定结直肠癌中,双体细胞错配修复基因突变(或杂合性缺失作为第二次打击)在t-CRC中检出7/10(70%),一般人群结直肠癌中检出8/36(22%,p=0.008)。

关键数值与推荐

  • t-CRC的微卫星不稳定频率为24%,一般人群结直肠癌为11%(p=0.003)。
  • t-CRC的MSH2/MSH6染色缺失率为13%,一般人群结直肠癌为1%(p<0.001)。
  • 无MLH1启动子甲基化的微卫星不稳定结直肠癌中,双体细胞错配修复基因突变在t-CRC中为7/10(70%),一般人群结直肠癌中为8/36(22%,p=0.008)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Hodgkin's lymphoma survivors who were treated with infradiaphragmatic radiotherapy or procarbazine-containing chemotherapy have a fivefold increased risk of developing colorectal cancer (CRC). This study aims to provide insight into the development of therapy-related CRC (t-CRC) by evaluating histopathological and molecular characteristics. DESIGN: 54 t-CRCs diagnosed in a Hodgkin's lymphoma survivor cohort were analysed for mismatch repair (MMR) proteins by immunohistochemistry, microsatellite instability (MSI) and KRAS/BRAF mutations. MSI t-CRCs were evaluated for promoter methylation and mutations in MMR genes. Pathogenicity of MMR gene mutations was evaluated by in silico predictions and functional analyses. Frequencies were compared with a general population cohort of CRC (n=1111). RESULTS: KRAS and BRAF mutations were present in 41% and 15% t-CRCs, respectively. Compared with CRCs in the general population, t-CRCs had a higher MSI frequency (24% vs 11%, p=0.003) and more frequent loss of MSH2/MSH6 staining (13% vs 1%, p<0.001). Loss of MLH1/PMS2 staining and MLH1 promoter methylation were equally common in t-CRCs and the general population. In MSI CRCs without MLH1 promoter methylation, double somatic MMR gene mutations (or loss of heterozygosity as second hit) were detected in 7/10 (70%) t-CRCs and 8/36 (22%) CRCs in the general population (p=0.008). These MMR gene mutations in t-CRCs were classified as pathogenic. MSI t-CRC cases could not be ascribed to Lynch syndrome. CONCLUSIONS: We have demonstrated a higher frequency of MSI among t-CRCs, which results from somatic MMR gene mutations. This suggests a novel association of somatic MMR gene mutations with prior anticancer treatment.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Rigter LS, Snaebjornsson P, Rosenberg EH, et al. Double somatic mutations in mismatch repair genes are frequent in colorectal cancer after Hodgkin's lymphoma treatment. Gut. 2016. PMID: 29439113. doi:10.1136/gutjnl-2016-312608

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。